My­lan wins ear­ly FDA OK of a Tec­fidera knock­off, and they're launch­ing with an eye to top­pling Bio­gen's block­buster fran­chise

Bio­gen $BI­IB just lost con­trol of its cash cow fran­chise.

On Tues­day, an­a­lysts were quick to no­tice that the FDA had flagged a full ap­proval of My­lan’s copy­cat of Tec­fidera, the big MS drug that George Scan­gos and team took over the goal line back in 2013. Last year that drug earned $4.4 bil­lion, about $4 of every $10 it earned in 2019. And bright and ear­ly Wednes­day morn­ing My­lan an­nounced that they are launch­ing the drug — even though they are do­ing it “at risk” as Bio­gen ap­peals the court rul­ing that scut­tled their at­tempt to re­tain patent pro­tec­tion to 2028.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER